Maxwell  Krakowiak net worth and biography

Maxwell Krakowiak Biography and Net Worth

Senior Vice President and Chief Financial Officer of Revvity

Max Krakowiak is SVP and Chief Financial Officer at Revvity, responsible for leading the Company's global finance organization.

Max is a team player who fosters a strong culture centered on camaraderie, talent development and winning the controllables. He has played an integral role on Revvity's finance leadership team since 2018. Before being appointed to his current role in August 2022, Max served as VP of Corporate Finance overseeing financial planning and analysis as well as the commercial and business development finance organizations. He has also served as the Company's chief of staff for finance and focused on driving global finance transformation through people, process and automation.

Prior to joining the Company, Max spent seven years at GE where he most recently served as a member of the executive leadership team in the company's corporate audit staff. He worked across GE's global operating segments to oversee teams responsible for corporate strategy, external investigations and investor relations. Max is also a graduate of the GE Financial Management leadership program.

Max holds a bachelor's degree in finance from Fordham University in New York City. He also spent time as a minor league baseball player in the Seattle Mariners organization.

What is Maxwell Krakowiak's net worth?

The estimated net worth of Maxwell Krakowiak is at least $2.10 million as of September 21st, 2026. Mr. Krakowiak owns 14,781 shares of Revvity stock worth more than $2,102,243 as of September 24th. This net worth approximation does not reflect any other investments that Mr. Krakowiak may own. Learn More about Maxwell Krakowiak's net worth.

How do I contact Maxwell Krakowiak?

The corporate mailing address for Mr. Krakowiak and other Revvity executives is 77 4th Avenue, Waltham, MA, 02451. Revvity can also be reached via phone at (781) 663-6900 and via email at [email protected]. Learn More on Maxwell Krakowiak's contact information.

Has Maxwell Krakowiak been buying or selling shares of Revvity?

Within the last three months, Maxwell Krakowiak has sold $235,728.43 of Revvity stock. Most recently, Maxwell Krakowiak sold 1,631 shares of the business's stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a transaction totalling $235,728.43. Following the completion of the sale, the insider now directly owns 14,781 shares of the company's stock, valued at $2,136,297.93. Learn More on Maxwell Krakowiak's trading history.

Who are Revvity's active insiders?

Revvity's insider roster includes Joel Goldberg (Insider), Maxwell Krakowiak (Senior Vice President and Chief Financial Officer), Prahlad Singh (Insider), and Tajinder Vohra (Insider). Learn More on Revvity's active insiders.

Are insiders buying or selling shares of Revvity?

In the last year, insiders at the sold shares 4 times. They sold a total of 9,126 shares worth more than $1,285,108.63. The most recent insider tranaction occured on September, 21st when insider Maxwell Krakowiak sold 1,631 shares worth more than $235,728.43. Insiders at Revvity own 0.9% of the company. Learn More about insider trades at Revvity.

Information on this page was last updated on 9/21/2026.

Maxwell Krakowiak Insider Trading History at Revvity

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2026Sell1,631$144.53$235,728.4314,781View SEC Filing Icon  
See Full Table

Maxwell Krakowiak Buying and Selling Activity at Revvity

This chart shows Maxwell Krakowiak's buying and selling at Revvity by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Revvity Company Overview

Revvity logo
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $142.23
Low: $140.08
High: $145.00

50 Day Range

MA: $122.53
Low: $106.57
High: $146.83

2 Week Range

Now: $142.23
Low: $81.22
High: $149.52

Volume

2,244,322 shs

Average Volume

2,016,186 shs

Market Capitalization

$15.87 billion

P/E Ratio

67.73

Dividend Yield

0.20%

Beta

1.09